Type 2 Diabetes Treatment in China for International Patients
Type 2 diabetes is usually managed rather than described as “cured,” but some people can achieve remission. China offers standard endocrinology, obesity and metabolic care, complication treatment, metabolic surgery in selected patients, and active research into new drugs and procedures.
Short answer: travelling to China makes the most sense when there is a defined reason —
difficult control, obesity and metabolic disease, serious complications, metabolic-surgery evaluation, a specialist
second opinion or interest in a specific research protocol. For routine medication adjustment alone, long-haul
medical travel is often unnecessary.
✓ Remission, not cure hype
✓ Standard care separated from research
✓ Named-hospital review
✓ No obligation to book
Type 2 Diabetes Treatment in China: At a Glance
Medication choice should reflect glycemic goals, weight, kidney and cardiovascular disease, hypoglycemia risk and other patient factors.
International consensus uses “remission,” not “cure,” when HbA1c remains below 6.5% for at least 3 months without usual glucose-lowering medication.
ADA 2026 treats weight management as a primary goal alongside glycemic management for people with Type 2 diabetes and overweight or obesity.
Current Chinese studies include remission-focused drug strategies and an investigational endoscopic pulse-electric-field approach in Shanghai.
Evidence and registry information last checked: September 2026.
Can Type 2 Diabetes Be Cured in China?
The more accurate medical term is remission. An international expert group convened by the ADA
proposed remission as HbA1c below 6.5% that persists for at least three months without usual glucose-lowering
pharmacotherapy. Remission does not mean diabetes can never return, so continued follow-up remains important.
China does not have a special universal “Type 2 diabetes cure” unavailable to the rest of medicine. What China does have is a large diabetes-care system, obesity and metabolic programmes, metabolic surgery, and active research into strategies aimed at improving glycemic control or achieving remission in selected patients.
Substantial and sustained weight loss
ADA 2026 notes that greater weight loss can have disease-modifying effects and may promote sustained Type 2 diabetes remission in some people.
A guaranteed permanent cure
Remission can relapse. A treatment advertisement promising permanent cure before reviewing disease duration, beta-cell function, weight and complications should be treated cautiously.
What Is Standard Type 2 Diabetes Treatment in China?
The foundation is not uniquely Chinese: treatment is individualized around glucose, weight, cardiovascular and kidney risk, complications and patient preferences. China may still be useful when a patient wants a tertiary specialist review or access to a specific programme.
| Treatment layer | What it can include | Why it matters for a medical traveller |
|---|---|---|
| Glucose-lowering medication | Metformin, GLP-1–based therapy, SGLT2 inhibitors, insulin and other agents according to the clinical situation. | A China trip should add specialist value, not merely duplicate a routine prescription that can be managed at home. |
| Weight management | Nutrition, activity, behavioral treatment and obesity pharmacotherapy when indicated. | Weight reduction can improve glucose control and, in some patients, contribute to remission. |
| Kidney / cardiovascular protection | Risk assessment and therapies selected for renal and cardiovascular benefit where appropriate. | Complex comorbidity can make a multidisciplinary tertiary hospital more relevant than a generic diabetes clinic. |
| Metabolic surgery | Gastric bypass, sleeve gastrectomy or another procedure in a carefully selected surgical candidate. | This is a major intervention requiring a high-volume multidisciplinary centre and long-term follow-up. |
| Clinical research | Investigational drugs, procedures or regenerative approaches under defined protocols. | Trial existence does not equal eligibility or foreign-patient access. |
Weight Loss, Obesity Treatment and Type 2 Diabetes Remission
For many people with Type 2 diabetes and overweight or obesity, weight management is part of diabetes treatment itself.
ADA 2026 recommends treating weight as a primary goal alongside glycemia. Sustained weight loss above 10% often
produces larger metabolic benefits and can have disease-modifying effects, including possible remission.
Useful when the goal is durable weight loss
Not every patient needs medical travel for this. The value of China depends on whether a hospital offers a structured specialist programme that adds something unavailable locally.
Modern incretin-based treatment
Current standards prioritize medications with meaningful glucose and weight benefits when clinically appropriate. Drug choice still depends on the patient’s full medical profile.
Potential remission pathway in selected patients
ADA 2026 supports metabolic surgery as a weight and glycemic-management option for appropriate people with Type 2 diabetes and obesity, performed in experienced multidisciplinary centres.
Remission is not guaranteed. Surgery and large weight loss can produce major glycemic improvement,
but remission rates vary by procedure and patient characteristics, and diabetes can recur over time.
China Research Focused on Type 2 Diabetes Remission
China has studied remission-oriented strategies for years. A multicentre randomized Chinese trial published in The Lancet in 2008 evaluated short-term intensive insulin treatment in newly diagnosed Type 2 diabetes specifically for beta-cell recovery and glycemic remission. Newer studies continue to use remission as an endpoint.
NCT07374328 · TRED
Triple hypoglycemic regimens in newly diagnosed Type 2 diabetes
This multicentre randomized study, sponsored by the Second Affiliated Hospital of Guangzhou Medical University, compares a semaglutide-based triple regimen with a sitagliptin-based triple regimen. The primary outcome is diabetes remission rate at 11 months.
| Registry detail | Public record | What it means |
|---|---|---|
| Registry ID | NCT07374328 | This is a defined hospital research protocol, not a general “China remission programme.” |
| Population | Newly diagnosed Type 2 diabetes; age 18–65; HbA1c ≥9.0% | The study is not designed for every person with established Type 2 diabetes. |
| Enrollment | Estimated 240 | Much larger than a single-case regenerative headline, but still a defined research population. |
| Primary outcome | Diabetes remission rate at 11 months | Remission is being measured explicitly rather than inferred from a marketing claim. |
| Registry status | Public record says Recruiting — verify | The record was last verified in January 2026 and listed estimated completion on August 31, 2026. Because that date has passed, current recruitment must be rechecked before any patient inquiry. |
| Foreign-patient access | Not established by the public registry | The study site must confirm whether an overseas patient can be screened and whether the follow-up schedule is feasible. |
Other Experimental Type 2 Diabetes Research in China
Research does not mean standard treatment. The examples below show why patients should identify the exact protocol rather than search for a generic “new diabetes treatment in China.”
Pulse electric field ablation study
Shanghai East Hospital lists a recruiting preliminary study of an investigational pulse-electric-field ablation system for adults with Type 2 diabetes with suboptimal drug control. It is a research procedure, not routine diabetes care.
HRS9531 tablet Phase II study
A 2026 randomized placebo-controlled HRS9531 tablet study is registered at Beijing Chaoyang Hospital and Qilu Hospital of Shandong University. The registry currently lists it as not yet recruiting.
Do not travel for a registry listing alone. Status can change, sites may have local participation
requirements, and the public record does not automatically establish acceptance of foreign self-pay patients.
What About Stem-Cell Therapy for Type 2 Diabetes?
Cell therapy is a separate research question. China has published and registered Type 2 diabetes studies involving mesenchymal stem cells, but there is no reliable universal “stem-cell success rate” that can be applied to commercial packages.
Defined protocol, defined population
For example, NCT02302599 was a randomized placebo-controlled Chinese UC-MSC study with explicit eligibility and outcome measures.
A generic commercial package success rate
A self-pay infusion should not inherit the results of an unrelated trial unless the exact cell product, dose, protocol and patient population match.
Researching a stem-cell offer for Type 2 diabetes?
Use our separate evidence guide to compare trials, published results and commercial packages.
Who May Have a Real Reason to Consider Treatment in China?
A defined clinical problem
- Poor control despite a well-documented treatment plan
- Type 2 diabetes plus severe obesity or complex metabolic disease
- Metabolic-surgery evaluation
- Diabetic kidney, cardiovascular or foot complications requiring multidisciplinary care
- A specific registered China trial you want screened
- A named Chinese hospital has already requested your records
A problem that can likely be managed locally
- Routine metformin or other medication refill
- Standard HbA1c monitoring
- Generic diet advice
- Buying a common diabetes drug more cheaply
- A “permanent cure” advertisement with no named hospital or protocol
- Travelling before a hospital or trial confirms the case
When Diabetes Complications Change the Hospital Choice
In medical tourism, the “best diabetes hospital” often depends less on diabetes itself and more on the complication that needs to be managed.
Diabetic kidney disease
May require nephrology, renal imaging, medication review or dialysis-related planning in addition to endocrinology.
Heart and vascular risk
Complex coronary or vascular disease can make a multidisciplinary tertiary hospital more appropriate.
Ulcer / infection / ischemia
A diabetic-foot case may need vascular, infectious-disease, surgery and wound-care capability, not only endocrinology.
Retinopathy
Ophthalmic treatment can be a separate reason for hospital selection and may change the urgency of the trip.
How Much Does Type 2 Diabetes Treatment in China Cost?
There is no fixed Type 2 package price. A routine outpatient assessment and laboratory work-up are
completely different from inpatient treatment, diabetic-foot surgery, kidney care, metabolic surgery or experimental research.
Our dedicated cost guide uses official Chinese public-service price examples and separates hospital charges from international-patient travel, interpretation and accommodation costs. For an actual case, the useful number is a written estimate from the named hospital after records review.
Need a case-specific Type 2 treatment estimate?
Send the recent records and what you want evaluated. We can ask a suitable hospital for expected costs when the case can be reviewed.
What to Send for a Type 2 Diabetes Case Review
Core diabetes information
- Age, height, weight and BMI
- Year of diagnosis
- Latest HbA1c
- Current medication and doses
- Current insulin dose if used
- C-peptide if available
- Recent kidney and liver function
Complications and treatment goal
- Kidney disease / urine albumin results
- Cardiovascular history
- Eye / retinopathy reports
- Diabetic-foot history
- Previous bariatric / metabolic treatment
- Whether your goal is remission, surgery, complications or trial screening
- Any China hospital, trial or commercial offer you already found
How Parkmega Handles a Type 2 Diabetes Case
Review the records
We identify the main problem: routine control, obesity/metabolic disease, complications, surgery or research.
Choose the right route
A diabetes centre is not automatically the right destination if the main issue is kidney disease, diabetic foot or metabolic surgery.
Ask a named centre
We check whether the hospital or research team will review an overseas case and what additional records are needed.
Get costs before travel
Hospital estimate, expected stay and travel planning come after the medical route is confirmed.
Have Type 2 Diabetes and Want to Know Whether China Offers a Useful Next Step?
Send your recent records and treatment goal. We’ll determine whether the case is best suited to standard endocrinology, metabolic treatment, complication care, surgery or a research inquiry before you plan travel.
✓ No cure guarantee
✓ Named-centre review
✓ Cost checked before travel
Related Diabetes Guides
Frequently Asked Questions
Short answers to the Type 2 diabetes questions international patients most often ask about China.
Can Type 2 diabetes be cured in China?
Type 2 diabetes is more accurately discussed in terms of remission rather than cure. International consensus defines remission as HbA1c below 6.5% for at least three months without usual glucose-lowering medication. Remission can occur in selected patients after major weight loss or other effective treatment, but it is not guaranteed and diabetes can recur.
What is the best treatment for Type 2 diabetes in China?
There is no single best treatment for every patient. The plan should reflect HbA1c, weight, kidney and cardiovascular disease, hypoglycemia risk, current medication, complications and personal treatment goals. For a medical traveller, the useful question is which Chinese centre fits the specific clinical problem.
Can weight loss put Type 2 diabetes into remission?
Yes, in some people. ADA 2026 notes that greater sustained weight loss can substantially improve glucose levels and may promote Type 2 diabetes remission. The probability varies with factors such as disease duration, beta-cell function, weight loss achieved and whether diabetes has already required insulin.
Is metabolic surgery used for Type 2 diabetes?
Yes, for selected surgical candidates with Type 2 diabetes and obesity. Current ADA guidance recognizes metabolic surgery as a weight and glycemic-management approach and recommends experienced, high-volume multidisciplinary centres. A Chinese hospital must still decide whether a specific international patient is an appropriate candidate.
Are there Type 2 diabetes clinical trials in China in 2026?
Yes. Examples include NCT07678866 at Shanghai East Hospital, a recruiting preliminary pulse-electric-field study for adults with suboptimal drug control, and NCT07599410, a Phase II HRS9531 tablet study registered at Beijing Chaoyang Hospital and Qilu Hospital but currently listed as not yet recruiting. Trial status and foreign-patient access must be checked before travel.
How much does Type 2 diabetes treatment cost in China?
There is no fixed national package price. Cost depends on whether the patient needs a routine specialist review, medication and weight management, complication treatment, hospital admission, metabolic surgery or experimental research. The most useful estimate is a written quote from a named hospital after medical-record review.
What records should I send for a Type 2 diabetes review in China?
Send your age, height, weight, year of diagnosis, latest HbA1c, current medication and insulin dose if used, kidney and liver function, C-peptide if available, major cardiovascular, eye, kidney or foot complications, and whether your goal is remission, surgery, complication care or research screening.
Evidence and Primary Sources
- American Diabetes Association — Standards of Care in Diabetes—2026, Section 8. Weight management is a primary treatment goal in Type 2 diabetes with overweight or obesity; greater sustained weight loss can have disease-modifying effects and may promote remission. Metabolic surgery is an evidence-based option for appropriate surgical candidates. ADA 2026 — Obesity and Weight Management.
- American Diabetes Association — Standards of Care in Diabetes—2026, Section 9. Individualized glucose-lowering therapy, including consideration of weight, kidney and cardiovascular disease. ADA 2026 — Pharmacologic Approaches.
- ADA-led international consensus — Definition and Interpretation of Remission in Type 2 Diabetes. Proposed remission criterion: HbA1c below 6.5% persisting for at least three months without usual glucose-lowering pharmacotherapy. Diabetes Care consensus report.
- Weng J. et al., The Lancet (2008), PMID 18502299. Multicentre randomized Chinese trial of transient intensive insulin treatment in newly diagnosed Type 2 diabetes, designed to examine beta-cell function and glycemic remission. PubMed record.
- ClinicalTrials.gov NCT07374328 — TRED. Multicentre randomized Guangzhou-sponsored study in newly diagnosed Type 2 diabetes with diabetes remission rate as the primary outcome. The registry says Recruiting, but its last verification was January 2026 and its estimated completion date was August 31, 2026, so current recruitment should be rechecked. ClinicalTrials.gov record.
- ClinicalTrials.gov NCT07678866. Recruiting preliminary study at Shanghai East Hospital of a pulse-electric-field ablation system for adults with Type 2 diabetes and suboptimal drug control. ClinicalTrials.gov record.
- ClinicalTrials.gov NCT07599410. Phase II placebo-controlled HRS9531 tablet study with sites at Beijing Chaoyang Hospital and Qilu Hospital of Shandong University; currently listed as not yet recruiting. ClinicalTrials.gov record.
Evidence note: a registry status, hospital publication or clinical study does not automatically establish that an international self-pay patient can enroll or buy the same intervention. Access must be confirmed with the exact hospital or study team.
Medical note: This page is for medical-travel research and hospital matching. It is not medical advice and should not be used to stop or change diabetes medication without the treating clinical team.
Want Us to Check Which China Treatment Route Fits Your Case?
Send your records and treatment goal. We’ll separate routine care from remission-focused treatment, complications, surgery and experimental research, then identify the next realistic step before you travel.